Actinium Pharmaceuticals, Inc. (ATNM) Income Statement
ATNM 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsATNM revenue and net income
Where ATNM's revenue goes
2025Each bar shows an amount and its share of revenue. ATNM kept −37,652.2% of revenue as net income.
ATNM profit margins
ATNM growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | −55.6% | −32.1% | — |
| Gross profit | — | −55.6% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ATNM quarterly EPS vs estimates
Actinium Pharmaceuticals beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.25).
ATNM income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $90,000 | $0 | $81,000 | $1.0M | $1.1M | $622,000 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $811,000 | $790,000 | $699,000 | $524,000 | $447,000 | $420,089 | $50,721 | $55,938 | $77,523 |
| Gross profit | $90,000 | −$811,000 | $81,000 | $1.0M | $620,000 | −$447,000 | −$420,089 | −$50,721 | −$55,938 | −$77,523 |
| Research & development | $21.1M | $30.0M | $38.7M | $23.1M | $17.5M | $16.1M | $16.5M | $17.1M | $17.7M | $17.5M |
| Sales, general & admin | $15.2M | $12.1M | $13.3M | $12.0M | $8.1M | $6.3M | $5.5M | $6.7M | $9.2M | $9.3M |
| Total operating expenses | $36.3M | $41.3M | $52.0M | $35.1M | $25.6M | $21.9M | $21.7M | $23.8M | $26.9M | $26.8M |
| Operating income | −$36.2M | −$42.1M | −$51.9M | −$34.1M | −$25.0M | −$22.4M | −$22.1M | −$23.8M | −$26.9M | −$26.8M |
| Interest income | $2.4M | $3.9M | $2.7M | $1.1M | $190,000 | $178,000 | $172,393 | $173,359 | $5,430 | $2.5M |
| Interest expense | — | — | — | $1.1M | $190,000 | $0 | $0 | $173,359 | $5,430 | $5,007 |
| Income before taxes | −$33.9M | −$38.2M | −$48.8M | −$33.0M | −$24.8M | −$22.2M | −$21.9M | −$23.7M | −$26.6M | −$24.3M |
| Income taxes | — | — | $622,105 | −$1.1M | −$190,000 | −$178,000 | −$172,000 | $173,359 | −$310,000 | $5,007 |
| Net income | −$33.9M | −$38.2M | −$48.8M | −$33.0M | −$24.8M | −$22.2M | −$21.9M | −$23.7M | −$26.6M | −$24.3M |
| EBITDA | −$33.1M | −$37.4M | −$48.0M | −$32.3M | −$24.2M | −$21.8M | −$21.5M | −$23.8M | −$26.9M | −$26.8M |
| EPS (diluted) | −$1.08 | −$1.27 | −$1.83 | −$1.37 | −$1.20 | −$2.04 | −$4.50 | −$6.60 | −$12.30 | −$15.30 |
| Gross margin | 100.0% | — | 100.0% | 100.0% | 54.2% | −71.9% | — | — | — | — |
| Operating margin | −40,274.4% | — | −64,098.8% | −3,311.1% | −2,182.2% | −3,600.2% | — | — | — | — |
| Net margin | −37,652.2% | — | −60,269.1% | −3,205.5% | −2,165.6% | −3,571.5% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.0M | $0 | $0 | $90,000 | $0 | $0 | $810,000 | $0 | $0 | $0 | $81,000 | $0 |
| Cost of revenue | $0 | $220,000 | −$615,000 | $206,000 | $204,000 | $205,000 | $204,000 | $202,000 | $189,000 | $216,000 | $199,000 | $200,000 |
| Gross profit | $35.0M | −$220,000 | $615,000 | $90,000 | −$204,000 | −$205,000 | −$204,000 | −$202,000 | −$189,000 | −$216,000 | −$118,000 | −$200,000 |
| Research & development | $5.4M | $4.2M | $4.9M | $4.2M | $4.9M | $7.7M | $4.6M | $9.6M | $8.6M | $6.4M | $7.9M | $11.4M |
| Sales, general & admin | $2.1M | $1.7M | $2.1M | $1.5M | $2.6M | $8.9M | $2.7M | $2.8M | $3.6M | $3.0M | $2.3M | $2.7M |
| Total operating expenses | $7.4M | $5.7M | $7.0M | $5.8M | $7.5M | $16.6M | $7.3M | $12.4M | $12.2M | $9.4M | $10.2M | $14.2M |
| Operating income | $27.6M | −$5.9M | −$6.4M | −$5.7M | −$7.5M | −$16.6M | −$7.5M | −$12.6M | −$12.4M | −$9.6M | −$10.3M | −$14.4M |
| Interest income | $336,000 | $381,000 | $474,000 | $561,000 | $625,000 | $700,000 | $853,000 | $1.0M | $1.1M | $927,000 | $1.0M | $1.1M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $547,000 | — |
| Income before taxes | $27.9M | −$5.5M | −$5.9M | −$5.1M | −$6.9M | −$15.9M | −$6.7M | −$11.6M | −$11.4M | −$8.7M | −$9.3M | −$13.3M |
| Income taxes | — | — | — | — | — | — | — | −$11.6M | — | $172,724 | $547,000 | $239,586 |
| Net income | $27.9M | −$5.5M | −$5.9M | −$5.1M | −$6.9M | −$15.9M | −$6.7M | −$11.6M | −$11.4M | −$8.7M | −$9.3M | −$13.3M |
| EBITDA | $28.1M | −$5.3M | −$5.7M | −$4.9M | −$6.7M | −$15.7M | −$6.4M | −$11.4M | −$11.2M | −$8.5M | −$9.1M | −$13.1M |
| EPS (diluted) | $0.89 | −$0.18 | −$0.19 | −$0.16 | −$0.22 | −$0.51 | −$0.21 | −$0.37 | −$0.38 | −$0.31 | −$0.33 | −$0.49 |
| Gross margin | 100.0% | — | — | 100.0% | — | — | −25.2% | — | — | — | −145.7% | — |
| Operating margin | 78.8% | — | — | −6,324.4% | — | — | −926.5% | — | — | — | −12,769.1% | — |
| Net margin | 79.7% | — | — | −5,701.1% | — | — | −821.2% | — | — | — | −11,511.1% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ATNM's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ATNM financial results
In fiscal year 2025 (ended December 31, 2025), Actinium Pharmaceuticals reported revenue of $0.1 million. It had a net loss of $33.9 million, a net profit margin of −37,652.2%. Diluted earnings per share came to −$1.08. Over five years revenue grew at an average rate of −32.1% a year.
See the ATNM stock overview for the latest quote and news, or the ATNM chart for price history and technical indicators.
ATNM income statement FAQ
What is Actinium Pharmaceuticals's annual revenue?
Actinium Pharmaceuticals reported total revenue of $0.1 million for fiscal year 2025, which ended on December 31, 2025.
Is Actinium Pharmaceuticals profitable?
No. Actinium Pharmaceuticals reported a net loss of $33.9 million in fiscal 2025, a net profit margin of −37,652.2%; its operating margin was −40,274.4%.
What is Actinium Pharmaceuticals's gross margin?
Actinium Pharmaceuticals's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Actinium Pharmaceuticals kept $100 after the direct cost of its products and services.
How much does Actinium Pharmaceuticals spend on research and development?
Actinium Pharmaceuticals spent $21.1 million on research and development in fiscal 2025, 23,471.1% of revenue.
How fast is Actinium Pharmaceuticals growing?
Revenue grew −32.1% a year on average over the last five fiscal years, from $0.6 million to $0.1 million.
What are Actinium Pharmaceuticals's earnings per share?
Actinium Pharmaceuticals earned $-1.08 per diluted share in fiscal 2025, compared with $-1.27 a year earlier.
When will Actinium Pharmaceuticals report its next earnings?
Actinium Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Actinium Pharmaceuticals's fiscal year end?
Actinium Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.